On October 17, 2019, Syros Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its decision to prioritize the development ofSY-5609 and to discontinue further development ofSY-1365. A copy of this press release is filed as Exhibit 99.1 to thisForm 8-K and incorporated herein by reference. The information contained on websites referenced in this press release is not incorporated herein.
On October 17, 2019, the Company held a conference call and webcast in which the Company’s management reviewed a slide presentation describing, among other things, data from the expansion portion of the Company’s Phase 1 clinical trial ofSY-1365, its intravenous CDK7 inhibitor, and preclinical data fromSY-5609, its oral CDK7 inhibitor. This slide presentation is attached as Exhibit 99.2 to thisForm 8-K and incorporated herein by reference.
Cautionary Note Regarding Forward-Looking Statements
This Form8-K contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Form8-K, including statements regarding the Company’s strategy, research and clinical development plans, future operations, prospects, plans and objectives of management, are forward-looking statements. The words “anticipate,” “believe,” “continue,” could,” “estimate,” “expect,” “hope,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “target,” “should,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including the Company’s ability to: advance the development of its programs, includingSY-5609, under the timelines it projects; demonstrate in clinical trials the requisite safety, efficacy and combinability ofSY-5609; successfully progressSY-5609 throughIND-enabling preclinical and toxicology studies; replicate scientific andnon-clinical data in clinical trials; obtain and maintain patent protection forSY-5609 and the freedom to operate under third party intellectual property; obtain and maintain necessary regulatory approvals; identify, enter into and maintain collaboration agreements with third parties; manage competition; manage expenses; raise the substantial additional capital needed to achieve its business objectives; attract and retain qualified personnel; and successfully execute on its business strategies; risks described under the caption “Risk Factors” in the Company’s Annual Report on Form10-K for the year ended December 31, 2018 and Quarterly Report on Form10-Q for the quarter ended June 30, 2019, each of which is on file with the Securities and Exchange Commission; and risks described in other filings that the Company makes with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise.
| Item 9.01 | Financial Statements and Exhibits. |
